Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 68,546,392
  • Shares Outstanding, K 106,955
  • Annual Sales, $ 8,497 M
  • Annual Income, $ 3,513 M
  • 60-Month Beta 0.16
  • Price/Sales 8.21
  • Price/Cash Flow 20.35
  • Price/Book 4.80
Trade REGN with:

Options Overview Details

View History
  • Implied Volatility 32.70%
  • Historical Volatility 19.66%
  • IV Percentile 48%
  • IV Rank 36.89%
  • IV High 48.55% on 10/05/20
  • IV Low 23.44% on 06/02/21
  • Put/Call Vol Ratio 0.77
  • Today's Volume 1,094
  • Volume Avg (30-Day) 2,124
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 16,130
  • Open Int (30-Day) 19,751

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 9.36
  • Number of Estimates 6
  • High Estimate 10.63
  • Low Estimate 8.01
  • Prior Year 7.68
  • Growth Rate Est. (year over year) +21.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
636.00 +1.72%
on 09/13/21
686.62 -5.78%
on 09/03/21
-16.32 (-2.46%)
since 08/20/21
3-Month
523.29 +23.63%
on 06/23/21
686.62 -5.78%
on 09/03/21
+112.68 (+21.09%)
since 06/21/21
52-Week
441.00 +46.70%
on 03/04/21
686.62 -5.78%
on 09/03/21
+91.25 (+16.42%)
since 09/21/20

Most Recent Stories

More News
AbbVie (ABBV) Files for Skyrizi in Crohn's Disease With FDA

AbbVie (ABBV) submits a regulatory application in the United States, seeking approval for Skyrizi in Crohn's disease.

REGN : 646.95 (+0.95%)
VRTX : 185.80 (+0.07%)
RGEN : 314.18 (+2.66%)
ABBV : 107.15 (+0.70%)
Biogen's (BIIB) Lucentis BioSimilar Byooviz Gets FDA Approval

Biogen (BIIB) announces the approval of Byooviz, its biosimilar referencing Roche's Lucentis, by the FDA.

REGN : 646.95 (+0.95%)
BIIB : 295.54 (-0.99%)
RHHBY : 45.9700 (+0.88%)
ABBV : 107.15 (+0.70%)
AstraZeneca (AZN) Up on Enhertu, Imfinzi Cancer Data at ESMO

AstraZeneca's (AZN) Enhertu reduces the risk of disease progression by 72% in HER2-positive metastatic breast cancer. Imfinzi plus chemotherapy triples patient survival at three years in ES-SCLC.

REGN : 646.95 (+0.95%)
AZN : 59.13 (+1.08%)
RHHBY : 45.9700 (+0.88%)
MRK : 71.97 (+0.06%)
Verrica (VRCA) Gets CRL From the FDA for Skin Disease Drug

Verrica (VRCA) suffers a setback yet again as the FDA issues a CRL for its lead product candidate VP-102. Consequently, shares are trading down.

REGN : 646.95 (+0.95%)
VRTX : 185.80 (+0.07%)
RGEN : 314.18 (+2.66%)
VRCA : 11.03 (-8.31%)
New Dupixent® (dupilumab) Data in Patients as Young as Six Years Old With Moderate-to-Severe Atopic Dermatitis to Be Presented at WCPD and EADV

and , /PRNewswire/ -- 

REGN : 646.95 (+0.95%)
Regeneron (REGN) Stock Moves -1.69%: What You Should Know

Regeneron (REGN) closed at $640.89 in the latest trading session, marking a -1.69% move from the prior day.

REGN : 646.95 (+0.95%)
Roche (RHHBY) Lung Cancer Drug Gets Positive CHMP Opinion

Roche (RHHBY) gets a positive CHMP opinion for Gavreto for the treatment of adult patients with RET fusion-positive advanced NSCLC.

REGN : 646.95 (+0.95%)
RHHBY : 45.9700 (+0.88%)
IRWD : 12.67 (+2.59%)
BPMC : 107.61 (+2.31%)
Bristol Myers' (BMY) Opdivo Combo for Gastric Cancer Gets CHMP Nod

Bristol Myers' (BMY) Opdivo, in combination with chemotherapy, gets positive CHMP recommendation by the EMA for treating adults with gastric cancer, among others.

REGN : 646.95 (+0.95%)
RHHBY : 45.9700 (+0.88%)
BMY : 60.33 (-0.28%)
MRK : 71.97 (+0.06%)
Biogen's (BIIB) MS Drug, Vumerity, Gets Positive CHMP Opinion

The CHMP gives a positive opinion on, and recommends granting marketing authorization to Biogen's (BIIB) Vumerity for the treatment of adults with relapsing-remitting multiple sclerosis.

REGN : 646.95 (+0.95%)
BIIB : 295.54 (-0.99%)
RHHBY : 45.9700 (+0.88%)
ALKS : 30.29 (+2.26%)
Glaxo's (GSK) Nucala Gets CHMP Nod for 3 Diseases in Europe

Glaxo (GSK) is seeking approval of Nucala for hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis) and chronic rhinosinusitis with nasal polyps in Europe

REGN : 646.95 (+0.95%)
SNY : 48.22 (+0.69%)
AZN : 59.13 (+1.08%)
GSK : 39.08 (+0.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma...

See More

Key Turning Points

3rd Resistance Point 668.99
2nd Resistance Point 662.92
1st Resistance Point 654.94
Last Price 646.95
1st Support Level 640.89
2nd Support Level 634.82
3rd Support Level 626.84

See More

52-Week High 686.62
Last Price 646.95
Fibonacci 61.8% 592.79
Fibonacci 50% 563.81
Fibonacci 38.2% 534.83
52-Week Low 441.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar